Q1 Earnings Estimate for WVE Issued By Leerink Partnrs

Wave Life Sciences Ltd. (NASDAQ:WVE) – Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Wave Life Sciences in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnings per share of ($0.28) for the quarter. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.12) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group assumed coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Stock Down 4.2 %

Shares of Wave Life Sciences stock opened at $7.74 on Monday. The business’s 50 day moving average is $10.61 and its 200-day moving average is $11.75. Wave Life Sciences has a 12-month low of $4.25 and a 12-month high of $16.74. The stock has a market cap of $1.19 billion, a P/E ratio of -6.97 and a beta of -1.04.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.34. The firm had revenue of $83.75 million for the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Insider Buying and Selling

In related news, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now directly owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Wave Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its stake in shares of Wave Life Sciences by 30.9% during the fourth quarter. California State Teachers Retirement System now owns 98,237 shares of the company’s stock valued at $1,215,000 after purchasing an additional 23,215 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Wave Life Sciences during the 4th quarter worth approximately $4,482,000. Polar Asset Management Partners Inc. grew its holdings in Wave Life Sciences by 14.7% during the 4th quarter. Polar Asset Management Partners Inc. now owns 557,323 shares of the company’s stock worth $6,894,000 after acquiring an additional 71,300 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Wave Life Sciences in the 4th quarter valued at approximately $40,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Wave Life Sciences by 14.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,238 shares of the company’s stock valued at $2,044,000 after acquiring an additional 20,520 shares during the last quarter. Institutional investors own 89.73% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.